GBA1 and Parkinson disease: Thus, the need for an evidence‐based and clinician‐supported consensus of recommendations on the disclosure of secondary disease associations with GBA1 variants, namely, PD, is timely, given the initiation of clinical trials for GBA1‐PD.14